Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
August 23, 2021 at 07:26 AM EDT
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|